Head-To-Head Survey: Cardiovascular Systems (CSII) vs. Its Competitors
Cardiovascular Systems (NASDAQ: CSII) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare Cardiovascular Systems to related companies based on the strength of its institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.
Valuation and Earnings
This table compares Cardiovascular Systems and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cardiovascular Systems||$204.91 million||$5.43 million||-442.09|
|Cardiovascular Systems Competitors||$827.23 million||$159.49 million||36.47|
Cardiovascular Systems’ competitors have higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
74.5% of Cardiovascular Systems shares are held by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 3.3% of Cardiovascular Systems shares are held by company insiders. Comparatively, 11.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Cardiovascular Systems and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cardiovascular Systems Competitors||-127.16%||-36.40%||-10.26%|
This is a breakdown of recent recommendations and price targets for Cardiovascular Systems and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cardiovascular Systems Competitors||174||1132||2476||89||2.64|
Cardiovascular Systems presently has a consensus price target of $34.25, indicating a potential upside of 29.10%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 8.85%. Given Cardiovascular Systems’ higher possible upside, equities research analysts plainly believe Cardiovascular Systems is more favorable than its competitors.
Risk & Volatility
Cardiovascular Systems has a beta of 2.54, indicating that its stock price is 154% more volatile than the S&P 500. Comparatively, Cardiovascular Systems’ competitors have a beta of 1.06, indicating that their average stock price is 6% more volatile than the S&P 500.
Cardiovascular Systems beats its competitors on 7 of the 12 factors compared.
About Cardiovascular Systems
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.